Skip to main content
Industry News

CTT Pharmaceutical Holdings, Inc., (CTTH) Announces National Patent Applications Worldwide for Orally Administrable Nanonized Opioids, Cannabinoids, Nutraceuticals and Other Pharmaceutical Agents

By January 15, 2019No Comments

Includes All Markets in which Aurora Cannabis Currently Operates or Contemplates Future Operations 

Hamilton, Ontario, Jan. 15, 2019 (GLOBE NEWSWIRE) — CTT Pharmaceutical Holdings, Inc., (“CTT”) (OTC:CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery systems, is pleased to announce that it has filed national patent applications that encompass over 50 countries for its titled “Orally Administrable Composition” technology.  This patent application broadly covers products such as Oral Thin Films, Wafers, Strips, Tablets, Gums etc. that deliver active nanonized pharmaceuticals including cannabinoids, opioids and most other large therapeutic molecules.

CTT filed an International Patent Application under the Patent Cooperation Treaty (“PCT”) on February 27, 2017 for an orally administrable composition comprising a nanonized therapeutic such as an opioid, cannabinoid and nutraceutical.  The application was published under the PCT on September 8, 2017 as WO 2017/147691.  Based on CTT’s International Patent Application under the PCT, CTT has moved into the “national phase” with applications in various countries around the world including in Europe, Australia, the Middle East, Africa, the Caribbean, and South America.  

“The initial patentability opinion received from the PCT office was positive, underscoring the novel nature of our technology and affirming our outlook to obtain patent acceptance in other countries in due course,” said Cam Birge, CEO of CTT Pharmaceutical. “This opinion is further supported by the issuance of a patent to CTT in Canada for our innovative oral thin film wafer technology, a fast dissolving, dose specific, smoke-free delivery of cannabis for the medical and Canadian Adult-use markets. Our oral thin film wafer is made from FDA approved non-medical ingredients used in several pharmaceutical formulations resulting in rapid onset of action within 5 minutes after dosing.”

About CTT Pharmaceutical

CTT’s patent portfolio currently contains five issued (three Canadian and two U.S.) patents with a number of national patent applications pending that encompass over fifty countries.  

Aurora Cannabis (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) currently has an approximate 9% equity ownership in CTT Pharma and holds a warrant enabling it to increase equity ownership up to 42.5% in CTT up until May 20, 2021.

CTT ‘s patent portfolio covers a nanonized orally administrable composition that can be applied to various delivery systems including a quick dissolving oral film forming agent that effectively delivers nanonized therapeutics to improve the bioavailability of therapeutic drugs that are difficult to deliver orally.  The main aim of CTT’s technology is the delivery of large therapeutic molecules such as proteins or cannabinoids.  This technology has been applied to cannabinoid delivery and has potential indications in pain management and opioid addiction management.

For more information, please visit our website:

CTT’s common shares trade on the OTC market in the United States under the symbol “CTTH”.

Forward looking statements 
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The company is under no obligation, and expressly disclaim any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

For more information, please contact:

Cam Birge – President,